Pullen Investment Management LLC Invests $403,000 in Humana Inc. (NYSE:HUM)

Pullen Investment Management LLC bought a new stake in shares of Humana Inc. (NYSE:HUM) during the first quarter, Holdings Channel.com reports. The fund bought 1,522 shares of the insurance provider’s stock, valued at approximately $403,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. FPC Investment Advisory Inc. purchased a new position in Humana during the fourth quarter worth approximately $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana in the fourth quarter valued at approximately $30,000. LFA Lugano Financial Advisors SA raised its stake in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the period. OFI Invest Asset Management acquired a new position in shares of Humana during the 4th quarter worth approximately $33,000. Finally, Riverview Trust Co purchased a new position in shares of Humana during the 1st quarter valued at approximately $34,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

NYSE:HUM opened at $234.87 on Friday. Humana Inc. has a one year low of $212.45 and a one year high of $406.46. The stock has a market cap of $28.35 billion, a PE ratio of 23.60, a P/E/G ratio of 2.05 and a beta of 0.43. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a 50 day moving average price of $250.43 and a 200 day moving average price of $262.89.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The company had revenue of $32.11 billion during the quarter, compared to analysts’ expectations of $32 billion. During the same period in the prior year, the business earned $7.23 EPS. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. Equities research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.51%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s dividend payout ratio is currently 25.04%.

Wall Street Analyst Weigh In

Several brokerages recently commented on HUM. JPMorgan Chase & Co. cut their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. Barclays cut their target price on shares of Humana from $273.00 to $268.00 and set an “equal weight” rating for the company in a research note on Thursday. Truist Financial reduced their price target on shares of Humana from $325.00 to $305.00 and set a “hold” rating for the company in a research report on Monday, May 12th. Finally, Mizuho lifted their price objective on Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday, April 9th. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Humana presently has an average rating of “Hold” and a consensus price target of $284.24.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.